{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-138931","form_type":"8-K","ticker":"MDGL","cik":"0001157601","company_name":"MADRIGAL PHARMACEUTICALS, INC.","filed_at":"2023-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.070545+00:00","generated_at":"2026-06-15T08:12:32.776086+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Madrigal Q1 cash burn $84.1M; resmetirom NDA on track for Q2 2023 with Breakthrough Therapy","bullets":["Cash and securities $329.5M at March 31, 2023, down from $358.8M at Dec 31, 2022.","Operating expenses $78.3M for Q1 2023, up from $57.6M in Q1 2022; R&D $62.2M, G&A $16.2M.","Resmetirom NDA for NASH with fibrosis remains on track for Q2 2023; FDA Breakthrough Therapy designation received.","MAESTRO-NASH trial enrollment complete; primary results to be presented at EASL in June 2023.","Interest income rose to $3.8M from $0.1M; interest expense $2.3M from loan facility."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-138931","json":"https://secwatch.observer/filing/0001193125-23-138931.json","markdown":"https://secwatch.observer/filing/0001193125-23-138931.md","text":"https://secwatch.observer/filing/0001193125-23-138931.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1157601/000119312523138931/0001193125-23-138931-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1157601/000119312523138931/d398921d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T08:12:32.776086+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"ccce31fc0df9ccbde5269df3fb8b85fcb0e95ddc","claim":"MADRIGAL PHARMACEUTICALS, INC. reported financial results for first quarter 2023.","evidence_excerpt":"On May 9, 2023, Madrigal Pharmaceuticals, Inc. (the “Company”) issued a press release announcing the Company’s financial results for the fiscal quarter ended March 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1157601/000119312523138931/0001193125-23-138931-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}